Literature DB >> 9497029

Conservation of structural motifs and antigenic diversity in the Plasmodium falciparum merozoite surface protein-3 (MSP-3).

D J McColl1, R F Anders.   

Abstract

Merozoite surface protein-3 (MSP-3) is a secreted polymorphic antigen associated with erythrocytic schizonts and merozoites of Plasmodium falciparum asexual blood-stages. A prominent structural feature of MSP-3 is a domain composed of three blocks of tandemly-repeated heptads with the consensus sequence AXXAXXX. The three blocks of four alanine heptad-repeats are separated by short stretches of non-repetitive sequence unrelated to the heptad-repeat. C-terminal to the heptad-repeats, MSP-3 contains a glutamic acid-rich domain followed by another heptad-repeat similar to a leucine-zipper motif. An analysis of the msp-3 gene from four P. falciparum isolates shows that polymorphism in MSP-3 is predominantly due to sequence diversity in the N-terminal half of the predicted polypeptide within and flanking the heptad-repeats. Mutations in the region of the gene that encodes the alanine heptad-repeats appear to be of two types. Unique mutations in non-repetitive sequence have generated amino acid substitutions and deletions that result in unique sequences among MSP-3 variants. In contrast, mutations in the heptad-coding sequence are largely dimorphic and are clustered in one or two heptads in each of the three blocks of heptads. Despite the diversity within and flanking the heptad domain the AXXAXXX motif is highly conserved as are other features of the sequence that predict the formation of alpha-helical secondary structure. Recombinant proteins and a synthetic peptide were used to raise antisera to conserved and variable regions of MSP-3. Differential reactivity of these reagents with the parasite antigen identified the alanine heptad-repeat domain as a site of antigenic diversity among MSP-3 polypeptides.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9497029     DOI: 10.1016/s0166-6851(97)00130-8

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  38 in total

1.  RAP1 controls rhoptry targeting of RAP2 in the malaria parasite Plasmodium falciparum.

Authors:  D L Baldi; K T Andrews; R F Waller; D S Roos; R F Howard; B S Crabb; A F Cowman
Journal:  EMBO J       Date:  2000-06-01       Impact factor: 11.598

2.  Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen.

Authors:  Régine Audran; Michel Cachat; Floriana Lurati; Soe Soe; Odile Leroy; Giampietro Corradin; Pierre Druilhe; François Spertini
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

3.  Plasmodium falciparum merozoite surface protein 1 (MSP-1)-MSP-3 chimeric protein: immunogenicity determined with human-compatible adjuvants and induction of protective immune response.

Authors:  Suman Mazumdar; Paushali Mukherjee; Syed Shams Yazdani; S K Jain; Asif Mohmmed; Virander Singh Chauhan
Journal:  Infect Immun       Date:  2009-11-23       Impact factor: 3.441

4.  Characterization of a protective Escherichia coli-expressed Plasmodium falciparum merozoite surface protein 3 indicates a non-linear, multi-domain structure.

Authors:  Chiawei W Tsai; Peter F Duggan; Albert J Jin; Nicholas J Macdonald; Svetlana Kotova; Jacob Lebowitz; Darrell E Hurt; Richard L Shimp; Lynn Lambert; Louis H Miller; Carole A Long; Allan Saul; David L Narum
Journal:  Mol Biochem Parasitol       Date:  2008-11-27       Impact factor: 1.759

5.  Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein.

Authors:  Soe Soe; Michael Theisen; Christian Roussilhon; Khin-Saw Aye; Pierre Druilhe
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

6.  Vaccine potentials of an intrinsically unstructured fragment derived from the blood stage-associated Plasmodium falciparum protein PFF0165c.

Authors:  S Olugbile; C Kulangara; G Bang; S Bertholet; E Suzarte; V Villard; G Frank; R Audran; A Razaname; I Nebie; O Awobusuyi; F Spertini; A V Kajava; I Felger; P Druilhe; G Corradin
Journal:  Infect Immun       Date:  2009-09-28       Impact factor: 3.441

7.  Population genetic analysis of large sequence polymorphisms in Plasmodium falciparum blood-stage antigens.

Authors:  Ambroise D Ahouidi; Amy K Bei; Daniel E Neafsey; Ousmane Sarr; Sarah Volkman; Dan Milner; Janet Cox-Singh; Marcelo U Ferreira; Omar Ndir; Zul Premji; Souleymane Mboup; Manoj T Duraisingh
Journal:  Infect Genet Evol       Date:  2009-11-30       Impact factor: 3.342

8.  Multiple var2csa-type PfEMP1 genes located at different chromosomal loci occur in many Plasmodium falciparum isolates.

Authors:  Adam F Sander; Ali Salanti; Thomas Lavstsen; Morten A Nielsen; Pamela Magistrado; John Lusingu; Nicaise Tuikue Ndam; David E Arnot
Journal:  PLoS One       Date:  2009-08-19       Impact factor: 3.240

9.  Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children.

Authors:  Sodiomon B Sirima; Alfred B Tiono; Alphonse Ouédraogo; Amidou Diarra; André Lin Ouédraogo; Jean Baptiste Yaro; Espérance Ouédraogo; Adama Gansané; Edith C Bougouma; Amadou T Konaté; Youssouf Kaboré; Abdoulaye Traoré; Roma Chilengi; Chilengi Roma; Issiaka Soulama; Adrian J F Luty; Pierre Druilhe; Simon Cousens; Issa Nébié
Journal:  PLoS One       Date:  2009-10-26       Impact factor: 3.240

10.  Design and pre-clinical profiling of a Plasmodium falciparum MSP-3 derived component for a multi-valent virosomal malaria vaccine.

Authors:  Marco Tamborrini; Markus S Mueller; Sabine A Stoffel; Nicole Westerfeld; Denise Vogel; Francesca Boato; Rinaldo Zurbriggen; John A Robinson; Gerd Pluschke
Journal:  Malar J       Date:  2009-12-30       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.